N303158 N3 Ruling Active

The tariff classification of Bicalutamide (CAS No. 90357-06-5), Linagliptin (CAS No. 668270-12-0) and Aripiprazole (CAS No. 129722-12-9) in bulk powder form, from India

Issued March 15, 2019 by U.S. Customs and Border Protection.

Tariff classification

HTS codes: 2930.90.2900, 2933.59.5300, 2933.79.0800

Headings: 2930, 2933

Product description

The first product, Bicalutamide is a non-steroidal anti-androgen. It is indicated for the treatment of metastatic carcinoma of the prostate. The second product, Linagliptin is a dipeptidyl peptidase-4 inhibitor. It is used in combination with diet and exercise for the treatment of type 2 diabetes mellitus. The third product, Aripiprazole is an atypical antipsychotic. It is indicated for the treatment of schizophrenia, bipolar mania and major depressive disorder.

CBP rationale

The applicable subheading for the Bicalutamide in bulk form will be 2930.90.2900, Harmonized Tariff Schedule of the United States (HTSUS), which provides for “Organo-sulfur compounds: Other: Aromatic: Other: Other. The applicable subheading for the Linagliptin in bulk form will be 2933.59.5300, HTSUS, which provides for “Heterocyclic compounds with nitrogen hetero-atom(s) only: Compounds containing a pyrimidine ring (whether or not hydrogenated) or piperazine ring in the structure: Other: Drugs: Aromatic or modified aromatic: Other. The applicable subheading for the Aripiprazole in bulk form will be 2933.79.0800, HTSUS, which provides for “Heterocyclic compounds with nitrogen hetero-atom(s) only: Lactams: Other lactams: Aromatic or modified aromatic: Other: Products described in additional U.

Full text

N303158 March 15, 2019 CLA-2-29:OT:RR:NC:N3:138 CATEGORY: Classification TARIFF NO.: 2930.90.2900; 2933.59.5300; 2933.79.0800 Mr. Gnanapragasam L Jeyaraj SST Corporation 635 Brighton Road Clifton, NJ 07012 RE: The tariff classification of Bicalutamide (CAS No. 90357-06-5), Linagliptin (CAS No. 668270-12-0) and Aripiprazole (CAS No. 129722-12-9) in bulk powder form, from India Dear Mr. Jeyaraj: In your letter dated February 21, 2019, you requested a tariff classification ruling. The first product, Bicalutamide is a non-steroidal anti-androgen. It is indicated for the treatment of metastatic carcinoma of the prostate. The second product, Linagliptin is a dipeptidyl peptidase-4 inhibitor. It is used in combination with diet and exercise for the treatment of type 2 diabetes mellitus. The third product, Aripiprazole is an atypical antipsychotic. It is indicated for the treatment of schizophrenia, bipolar mania and major depressive disorder. The applicable subheading for the Bicalutamide in bulk form will be 2930.90.2900, Harmonized Tariff Schedule of the United States (HTSUS), which provides for “Organo-sulfur compounds: Other: Aromatic: Other: Other.” Pursuant to General Note 13, HTS, the rate of duty will be free. The applicable subheading for the Linagliptin in bulk form will be 2933.59.5300, HTSUS, which provides for “Heterocyclic compounds with nitrogen hetero-atom(s) only: Compounds containing a pyrimidine ring (whether or not hydrogenated) or piperazine ring in the structure: Other: Drugs: Aromatic or modified aromatic: Other.” Pursuant to General Note 13, HTS, the rate of duty will be free. The applicable subheading for the Aripiprazole in bulk form will be 2933.79.0800, HTSUS, which provides for “Heterocyclic compounds with nitrogen hetero-atom(s) only: Lactams: Other lactams: Aromatic or modified aromatic: Other: Products described in additional U.S. note 3 to section VI.” Pursuant to General Note 13, HTS, the rate of duty will be free. Duty rates are provided for your convenience and are subject to change. The text of the most recent HTSUS and the accompanying duty rates are provided on the World Wide Web at https://hts.usitc.gov/current. This merchandise may be subject to the Federal Food, Drug, and Cosmetic Act and/or The Public Health Security and Bioterrorism Preparedness and Response Act of 2002 (The Bioterrorism Act), which are administered by the U.S. Food and Drug Administration (FDA). Information on the Federal Food, Drug, and Cosmetic Act, as well as The Bioterrorism Act, can be obtained by calling the FDA at 1-888-463-6332, or by visiting their website at www.fda.gov. This ruling is being issued under the provisions of Part 177 of the Customs Regulations (19 C.F.R. 177). A copy of the ruling or the control number indicated above should be provided with the entry documents filed at the time this merchandise is imported. If you have any questions regarding the ruling, contact National Import Specialist Judy Lee at [email protected]. Sincerely, Steven A. Mack Director National Commodity Specialist Division

View original on CBP CROSS →

More rulings on the same tariff codes

Searching CBP rulings the smart way

TariffLens semantically searches all 200,000+ CBP rulings, surfaces the ones that actually match your product, and builds defensible classifications backed by ruling citations.

Book a demo →